Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right 
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
AI is driving down the price of knowledge – universities have to rethink what they offer 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
